tiprankstipranks
Trending News
More News >
Solid Biosciences (SLDB)
NASDAQ:SLDB
US Market

Solid Biosciences (SLDB) Stock Forecast & Price Target

Compare
1,346 Followers
See the Price Targets and Ratings of:

SLDB Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Solid
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SLDB Stock 12 Month Forecast

Average Price Target

$16.25
▲(257.93%Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $16.25 with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 257.93% change from the last price of $4.54.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.65,4.907692307692308,6.165384615384616,7.423076923076923,8.680769230769231,9.938461538461539,11.196153846153848,12.453846153846156,13.711538461538463,14.969230769230771,16.22692307692308,17.484615384615385,18.742307692307694,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.65,4.619230769230769,5.588461538461538,6.5576923076923075,7.526923076923077,8.496153846153845,9.465384615384615,10.434615384615384,11.403846153846153,12.373076923076923,13.342307692307692,14.311538461538461,15.28076923076923,{"y":16.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.65,4.138461538461538,4.6269230769230765,5.115384615384615,5.6038461538461535,6.092307692307692,6.5807692307692305,7.069230769230769,7.5576923076923075,8.046153846153846,8.534615384615384,9.023076923076923,9.51153846153846,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.77,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.54,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$16.25Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on SLDB
Anupam RamaJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/21/25
Solid Biosciences: Undervalued Gem with Promising Gene Therapy Pipeline and Upcoming Catalysts
Truist Financial Analyst forecast on SLDB
Joon LeeTruist Financial
Truist Financial
$16
Buy
252.42%
Upside
Reiterated
05/16/25
Truist Securities reiterates Buy Rating on Solid Biosciences (SLDB)Truist Securities analyst Joon Lee reiterated a Buy rating and $16.00 price target on Solid Biosciences (NASDAQ: SLDB).
Leerink Partners Analyst forecast on SLDB
Joseph SchwartzLeerink Partners
Leerink Partners
$20
Buy
340.53%
Upside
Reiterated
05/16/25
Solid Biosciences' SGT-003 Therapy Shows Promise in DMD Treatment, Earning Buy Rating from Analyst
H.C. Wainwright Analyst forecast on SLDB
Arthur He CFAH.C. Wainwright
H.C. Wainwright
$20
Buy
340.53%
Upside
Reiterated
05/16/25
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating
Jefferies
$16$15
Buy
230.40%
Upside
Reiterated
05/16/25
Solid Biosciences (SLDB) PT Lowered to $15 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Solid Biosciences (NASDAQ: SLDB) to $15.00 (from $16.00) while maintaining a Buy rating.
Wedbush
$17
Buy
274.45%
Upside
Reiterated
05/16/25
Wedbush Sticks to Its Buy Rating for Solid Biosciences (SLDB)
Barclays Analyst forecast on SLDB
Gena WangBarclays
Barclays
$15$10
Buy
120.26%
Upside
Reiterated
05/16/25
Barclays Reaffirms Their Buy Rating on Solid Biosciences (SLDB)
William Blair Analyst forecast on SLDB
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/16/25
Solid Biosciences: Promising Developments and Potential Growth in Duchenne Muscular Dystrophy Treatment
Piper Sandler Analyst forecast on SLDB
Biren AminPiper Sandler
Piper Sandler
$20$17
Buy
274.45%
Upside
Reiterated
05/16/25
Solid Biosciences price target lowered to $17 from $20 at Piper SandlerSolid Biosciences price target lowered to $17 from $20 at Piper Sandler
Citizens JMP Analyst forecast on SLDB
Silvan TuerkcanCitizens JMP
Citizens JMP
$15
Buy
230.40%
Upside
Reiterated
05/16/25
Solid Biosciences (SLDB) Gets a Buy from Citizens JMP
Chardan Capital Analyst forecast on SLDB
Geulah LivshitsChardan Capital
Chardan Capital
$16
Buy
252.42%
Upside
Reiterated
03/07/25
Solid Biosciences (SLDB) Gets a Buy from Chardan CapitalUpdating our model for 4Q24 and FY24 financials leaves our PT at $16.
Citi
$16$20
Buy
340.53%
Upside
Reiterated
03/07/25
Solid Biosciences price target raised to $20 from $16 at H.C. WainwrightSolid Biosciences price target raised to $20 from $16 at H.C. Wainwright
Deutsche Bank  Analyst forecast on SLDB
David HoangDeutsche Bank
Deutsche Bank
$16
Buy
252.42%
Upside
Reiterated
07/17/24
Solid Biosciences' SGT-003: A Promising Leap in DMD Therapy with Cardiac Safety Superiority
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on SLDB
Anupam RamaJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/21/25
Solid Biosciences: Undervalued Gem with Promising Gene Therapy Pipeline and Upcoming Catalysts
Truist Financial Analyst forecast on SLDB
Joon LeeTruist Financial
Truist Financial
$16
Buy
252.42%
Upside
Reiterated
05/16/25
Truist Securities reiterates Buy Rating on Solid Biosciences (SLDB)Truist Securities analyst Joon Lee reiterated a Buy rating and $16.00 price target on Solid Biosciences (NASDAQ: SLDB).
Leerink Partners Analyst forecast on SLDB
Joseph SchwartzLeerink Partners
Leerink Partners
$20
Buy
340.53%
Upside
Reiterated
05/16/25
Solid Biosciences' SGT-003 Therapy Shows Promise in DMD Treatment, Earning Buy Rating from Analyst
H.C. Wainwright Analyst forecast on SLDB
Arthur He CFAH.C. Wainwright
H.C. Wainwright
$20
Buy
340.53%
Upside
Reiterated
05/16/25
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating
Jefferies
$16$15
Buy
230.40%
Upside
Reiterated
05/16/25
Solid Biosciences (SLDB) PT Lowered to $15 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Solid Biosciences (NASDAQ: SLDB) to $15.00 (from $16.00) while maintaining a Buy rating.
Wedbush
$17
Buy
274.45%
Upside
Reiterated
05/16/25
Wedbush Sticks to Its Buy Rating for Solid Biosciences (SLDB)
Barclays Analyst forecast on SLDB
Gena WangBarclays
Barclays
$15$10
Buy
120.26%
Upside
Reiterated
05/16/25
Barclays Reaffirms Their Buy Rating on Solid Biosciences (SLDB)
William Blair Analyst forecast on SLDB
Sami CorwinWilliam Blair
William Blair
Buy
Reiterated
05/16/25
Solid Biosciences: Promising Developments and Potential Growth in Duchenne Muscular Dystrophy Treatment
Piper Sandler Analyst forecast on SLDB
Biren AminPiper Sandler
Piper Sandler
$20$17
Buy
274.45%
Upside
Reiterated
05/16/25
Solid Biosciences price target lowered to $17 from $20 at Piper SandlerSolid Biosciences price target lowered to $17 from $20 at Piper Sandler
Citizens JMP Analyst forecast on SLDB
Silvan TuerkcanCitizens JMP
Citizens JMP
$15
Buy
230.40%
Upside
Reiterated
05/16/25
Solid Biosciences (SLDB) Gets a Buy from Citizens JMP
Chardan Capital Analyst forecast on SLDB
Geulah LivshitsChardan Capital
Chardan Capital
$16
Buy
252.42%
Upside
Reiterated
03/07/25
Solid Biosciences (SLDB) Gets a Buy from Chardan CapitalUpdating our model for 4Q24 and FY24 financials leaves our PT at $16.
Citi
$16$20
Buy
340.53%
Upside
Reiterated
03/07/25
Solid Biosciences price target raised to $20 from $16 at H.C. WainwrightSolid Biosciences price target raised to $20 from $16 at H.C. Wainwright
Deutsche Bank  Analyst forecast on SLDB
David HoangDeutsche Bank
Deutsche Bank
$16
Buy
252.42%
Upside
Reiterated
07/17/24
Solid Biosciences' SGT-003: A Promising Leap in DMD Therapy with Cardiac Safety Superiority
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Solid Biosciences

1 Month
xxx
Success Rate
3/11 ratings generated profit
27%
Average Return
-0.24%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 27.27% of your transactions generating a profit, with an average return of -0.24% per trade.
3 Months
xxx
Success Rate
4/9 ratings generated profit
44%
Average Return
+5.54%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 44.44% of your transactions generating a profit, with an average return of +5.54% per trade.
1 Year
Sami CorwinWilliam Blair
Success Rate
3/6 ratings generated profit
50%
Average Return
+5.17%
reiterated a buy rating 24 days ago
Copying Sami Corwin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +5.17% per trade.
2 Years
xxx
Success Rate
3/6 ratings generated profit
50%
Average Return
+5.17%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +5.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLDB Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
15
15
20
14
17
Buy
7
8
8
5
6
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
23
28
19
23
In the current month, SLDB has received 23 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SLDB average Analyst price target in the past 3 months is 16.25.
Each month's total comprises the sum of three months' worth of ratings.

SLDB Financial Forecast

SLDB Earnings Forecast

Next quarter’s earnings estimate for SLDB is -$0.50 with a range of -$0.59 to -$0.42. The previous quarter’s EPS was -$0.59. SLDB beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year SLDB has Outperformed its overall industry.
Next quarter’s earnings estimate for SLDB is -$0.50 with a range of -$0.59 to -$0.42. The previous quarter’s EPS was -$0.59. SLDB beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year SLDB has Outperformed its overall industry.

SLDB Sales Forecast

Next quarter’s sales forecast for SLDB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SLDB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year SLDB has Preformed in-line its overall industry.
Next quarter’s sales forecast for SLDB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SLDB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.54% of the time in the same period. In the last calendar year SLDB has Preformed in-line its overall industry.

SLDB Stock Forecast FAQ

What is SLDB’s average 12-month price target, according to analysts?
Based on analyst ratings, Solid Biosciences’s 12-month average price target is 16.25.
    What is SLDB’s upside potential, based on the analysts’ average price target?
    Solid Biosciences has 257.93% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SLDB a Buy, Sell or Hold?
          Solid Biosciences has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Solid Biosciences’s price target?
            The average price target for Solid Biosciences is 16.25. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 257.93% Increase from the current price of $4.54.
              What do analysts say about Solid Biosciences?
              Solid Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of SLDB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis